vložky egosan lady super
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky lady egosan light extra
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky lady egosan light mini
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky lady egosan light normal
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky lady egosan light super
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky obdĺžnikové egosan extra
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky obdĺžnikové egosan extra
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
vložky obdĺžnikové egosan night
santex s.p.a. via s. giovanni sul muro 1 202 21 milano taliansko -
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastické činidlá - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.